CliffBio
small molecule

TALZENNA

TALAZOPARIB TOSYLATE

Loss of exclusivityOctober 2031latest FDA-listed patent expiry
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameTALZENNA
Active ingredientTALAZOPARIB TOSYLATE
StrengthEQ 0.75MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2021
Marketing statusDISCN

Listed patents

PatentExpiresType
8735392October 2031substance, product
10189837October 2031substance, product
9820985July 2029use U-2437
8012976July 2029substance, product
8420650July 2029substance, product

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TALZENNA patent cliff — loss of exclusivity October 2031 | CliffBio